News & Events
-
-
Congressional Testimony 2012
This section includes testimony by FDA officials before House and Senate Committees and Subcommittees.
-
April 2012
- 04/18/2012
FDA User Fees 2012: How Innovation Helps Patients and Jobs (JW)
Janet Woodcock, M.D., before the House Committee on Energy and Commerce, Subcommittee on Health - 04/18/2012
FDA User Fees 2012: How Innovation Helps Patients and Jobs (JS)
Jeffrey Shuren, M.D., J.D., before the House Committee on Energy and Commerce, Subcommittee on Health
-
-
March 2012
- 03/29/2012
FDA User Fee Agreements: Strengthening FDA and the Medical Products Industry for the Benefit of Patients (JS)
Jeffrey Shuren, M.D., J.D., before the Senate Committee on Health, Education, Labor, and Pensions - 03/29/2012
FDA User Fee Agreements: Strengthening FDA and the Medical Products Industry for the Benefit of Patients (JW)
Janet Woodcock, M.D., before the Senate Committee on Health, Education, Labor, and Pensions - 03/28/2012
Hearing on H.R. 4223, the “Safe Doses Act”; H.R. 3668, the “Counterfeit Drug Penalty Enhancement Act of 2011”; and H.R. 4216, the “Foreign Counterfeit Prevention Act”
Dara A. Corrigan, J.D., before the House Committee on the Judiciary, Subcommittee on Crime, Terrorism, and Homeland Security - 03/27/2012
Examining the Current State of Cosmetics
Michael M. Landa, J.D., before the House Committee on Energy and Commerce, Subcommittee on Health - 03/08/2012
FDA User Fees 2012: Hearing on Issues Related to Accelerated Approval, Medical Gas, Antibiotic Development and Downstream Pharmaceutical Supply Chain
Janet Woodcock, M.D., before the House Committee on Energy and Commerce, Subcommittee on Health
-
-
February 2012
- 02/29/2012
President's Fiscal Year 2013 Budget Request for FDA
Margaret A. Hamburg, M.D., before the Committee on Appropriations, Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies - 02/15/2012
Reauthorization of MDUFA: What it Means for Jobs, Innovation and Patients
Jeffrey Shuren, M.D., J.D., before the House Committee on Energy and Commerce, Subcommittee on Health - 02/09/2012
Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages
Janet Woodcock, M.D., before the House Committee on Energy and Commerce, Subcommittee on Health - 02/01/2012
Reauthorization of PDUFA: What It Means for Jobs, Innovation, and Patients
Margaret A. Hamburg, M.D., before the House Committee on Energy and Commerce, Subcommittee on Health
-
Contact FDA
301-796-8900
Office of Legislation
Office of the Commissioner
10903 New Hampshire Avenue
White Oak 32
Rm. 2346
Silver Spring, MD 20993
-
-